News

Press Releases

Carmot Therapeutics Appoints Michael Gray as Chief Financial Officer and Chief Operating Officer
Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes
Carmot Therapeutics to Present Clinical Data from its Pipeline of Treatments for Obesity and Diabetes at the 83rd American Diabetes Association Scientific Sessions
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease
Carmot Therapeutics Announces Significant Leadership Team Expansion with Anne Phillips, MD, FRCPC Previously SVP Novo Nordisk, Joining the Board of Directors and Heather Turner, J.D. Joining as COO
Carmot Therapeutics closes $160 million Series D financing to advance clinical pipeline of novel incretin receptor modulators
Carmot announces Tim Garnett M.D., previously Chief Medical Officer Eli Lilly, joins Carmot’s Board of Directors.
Carmot to receive royalty payments upon sales of Amgen’s FDA approved first-in-class KRAS G12C Inhibitor, LUMAKRAS™ (sotorasib); Further demonstrates the value of Carmot’s therapeutic platform
Carmot Therapeutics Initiates the Clinical Program for CT-388, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Patients with Type 2 Diabetes and Showcases its Technology at the Upcoming American Diabetes Association Scientific Session
Carmot Therapeutics Announces Investigational New Drug (IND) Clearance for CT-868, a Dual GLP-1 and GIP Receptor Modulator for the Treatment of Overweight and Obese Patients with Type 2 Diabetes